Presentations

      Tobacco Harm Reduction: An Overview of PMI’s Scientific Approach & Main Results for the Tobacco Heating System (THS) 2.2, a Candidate Modified Risk Tobacco Product

      Fazenda, N.

      Conference date
      Nov 10, 2018
      Conference name
      46th Maghreb Medical Congress
      Link to more information
      Topic
      Summary

      The policy of tobacco harm reduction – making less harmful products available to smokers who would otherwise continue smoking – has the potential to be beneficial to public health, provided that (1) risk reduction is established by sound science and (2) smokers find these products satisfying as alternatives to smoking cigarettes. Philip Morris International (PMI) has developed a portfolio of products with the potential to reduce the risk of cigarette smoking-related diseases. One such product, the Tobacco Heating System (THS) 2.2 heats tobacco without combustion, and the subsequent formation of harmful and potentially harmful constituents (HPHC) is greatly reduced compared with cigarette smoke. Assessment of the THS2.2 aerosol in vitro and in vivo reveals reduced toxicity and no new hazards. Additional mechanistic endpoints, measured as part of in vivo studies, confirmed reduced impact on smoking-related disease networks. Clinical studies have confirmed the reduced exposure to HPHCs in smokers switching to THS2.2 together with additional studies comparing the impact of switching on markers of disease risk. Additional elements of the integrated scientific assessment program include studies on risk perception and behavior for THS2.2 and post-market assessment studies.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.